EPIRUS Biopharmaceuticals, Inc.
Limited financial coverage for EPRSQ.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
EPIRUS Biopharmaceuticals, Inc. was a global pharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of biosimilar therapeutics. Its primary experimental compound was BOW015, a biosimilar counterpart to Remicade (infliximab), intended for the treatment of various inflammatory conditions.
- CEO
- Jeff Kagy
- IPO
- 2005
- Employees
- 73
- HQ
- Boston, MA, US
Price Chart
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -14.11
- Avg Volume
- 0
Get TickerSpark's AI analysis on EPRSQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EPRSQ coverage
Recent articles, reports, and earnings notes.
No research on EPRSQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPRSQ report →Similar companies
Peers in the same neighborhood.